Fluvastatin promotes chondrogenic differentiation of adipose-derived mesenchymal stem cells by inducing bone morphogenetic protein 2

Masanari Kuwahara,Yukio Akasaki,Norio Goto,Ichiro Kurakazu,Takuya Sueishi,Masakazu Toya,Taisuke Uchida,Tomoaki Tsutsui,Ryota Hirose,Hidetoshi Tsushima,Yasuharu Nakashima
DOI: https://doi.org/10.1186/s40360-022-00600-7
2022-08-10
BMC Pharmacology and Toxicology
Abstract:Adipose-derived mesenchymal stem cells (ADMSCs) are a promising source of material source for medical regeneration of cartilage. Growth factors, including transforming growth factor-β (TGFβ) subfamily members and bone morphogenetic proteins (BMPs), play important roles in inducing and promoting chondrogenic differentiation of MSCs. However, these exogenous growth factors have some drawbacks related to their cost, biological half-life, and safety for clinical application. Several studies have reported that statins, the competitive inhibitors of 3-hydroxy-2-methylglutaryl coenzyme A (HMG-CoA) reductase, induce the expression of BMP2 in multiple cell types as the pleotropic effects. The objective of this study was to investigate the effects of fluvastatin during chondrogenic differentiation of human ADMSCs (hADMSCs).
pharmacology & pharmacy,toxicology
What problem does this paper attempt to address?